New medication targets belly fat
Researchers have revealed an experimental injection called "CBL-514" for weight loss, which works by directly destroying fat cells and reducing both subcutaneous fat and visceral fat surrounding internal organs. Second-phase trials showed that about 70% of participants experienced significant fat loss, with an average reduction of 12% in visceral fat after one month of treatment, along with improvements in health indicators such as blood pressure and cholesterol levels. The results suggest that the drug may be effective in reducing weight and fat in a healthy manner, with mild side effects including redness and pain at the injection site. However, larger and longer-term studies are still necessary to ensure safety and efficacy over time. Phase three clinical trials are underway to further evaluate the drug on a broader scale.
Notice: This Is an AI-Generated Summary
Comments (0)